Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocriplasmin outcomes in adults with vitreomacular traction or symptomatic vitreomacular adhesion
NL-OMON40974Phase 4Active, not recruiting
- Sponsor
- Alcon Inc.
- Start
- Jul 2014
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ocriplasmin in vitreomacular traction (VMT) and vitreomacular adhesion (VMA), sponsored by Alcon Inc. Primary endpoint: Nonsurgical resolution of focal VMT/sVMA at Day 28. Started Jul 2014; status: active, not recruiting.
02
Drugs
ocriplasmin
03
Conditions
vitreomacular traction (VMT)vitreomacular adhesion (VMA)
Beyond the preview
Go deeper on NL-OMON40974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40974.